Evidence map›Paper›PMID 42093999›Full record

ArticleFrontiers in immunology2026

Studies of chitosan-Prussian blue nanozyme in auditory protection: from cellular mechanisms to

Yong Li, Na Wang, Pengcheng Ren, Yueyi Zhai, Peng Xie, Chunhuan Zhang, Yan Qu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yong Li *Department of Otolaryngology, Hebei Medical University, Shijiazhuang, China.
Na Wang *Department of Otolaryngology, Hebei Medical University, Shijiazhuang, China.
Pengcheng RenDepartment of Joint Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yueyi ZhaiAnimal Laboratory, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Peng XieThe Third Hospital of Hebei Medical University, Shijiazhuang, China.
Chunhuan ZhangThe Third Hospital of Hebei Medical University, Shijiazhuang, China.
Yan QuDepartment of Otolaryngology, Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress and inflammation are interconnected drivers of cellular damage in pathologies ranging from neurodegenerative disorders to sensorineural hearing loss. We aimed to develop a chitosan-Prussian blue nanozyme (CS-PB) to target these processes in sensorineural hearing loss. CS-PB (35 μg/mL) pretreatment of H

Indexed as

ChitosanFerrocyanidesHearing Loss, SensorineuralAnimalsApoptosisCell LineCochleaHydrogen PeroxideMaleMiceOxidative StressRatsReactive Oxygen SpeciesSignal TransductionToll-Like Receptor 4Chitosanferric ferrocyanideFerrocyanidesHydrogen PeroxideReactive Oxygen SpeciesToll-Like Receptor 4auditory protectionchitosan-Prussian blue nanozymeinflammationoxidative stresstoll-like receptor 4/nuclear factor-κB pathway

Identifiers

PMID42093999
PMCPMC13139334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.